FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983707920> ?p ?o ?g. }

• W2983707920 endingPage "34" @default.
• W2983707920 startingPage "32" @default.
• W2983707920 abstract "INTRODUCTION: The outcome of patients (pts) with relapsed or refractory AML (R/R AML) or MDS after failing hypomethylating agents (HMA) and/or BCL-2 inhibitor combinations is poor. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, approved by the US Food and Drug Administration (FDA) for newly diagnosed therapy related AML or AML with myelodysplastic related changes. GO is a humanized immunoglobulin G4 antibody directed against CD33 and conjugated to the DNA toxin calicheamicin, also approved by the FDA for the treatment of newly diagnosed or R/R CD33-positive AML. We have hypothesized that the combination of CPX-351 and GO could induce superior antitumor efficacy compared to either agent alone for this patient population. GOALS: To determine the safety and efficacy of CPX-351 in combination with GO in relapsed refractory pts with AML and post-HMA failure HR-MDS. METHODS: This is a single arm and single institution, pilot study (NCT03672539) enrolling patients with CD33 positive R/R AML, post-HMA failure High-Risk MDS (&gt;10% blasts), and pts with newly diagnosed secondary AML after receiving HMA therapy. Patients received induction cycle CPX-351 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) administered via intravenous (IV) infusion on days 1, 3, and 5. GO was administered at a dose of 3 mg/m2 (capped at one 4.5 mg vial) IV on day 1. Pts not attaining complete remission (CR) or CR with incomplete count recovery (CRi) after 1 cycle, could receive a 2nd induction cycle of CPX-351 at the same dose, but only on days 1 and 3 with GO 3 mg/m2 on day 1. Patients attaining CR/CRi could receive up to 2 consolidation cycles, after a minimum of 4 weeks from the start of the last cycle with CPX-351 (daunorubicin 29 mg/m2 and cytarabine 65 mg/m2) IV on days 1 and 3, and GO at 3 mg/m2 on day 1. GO was only administered during the second consolidation cycle if there was evidence of minimal residual disease (+MRD). GO could also be administered as a single agent for maintenance treatment on day 1 every 6 weeks, in case of persistent detection of MRD. RESULTS: Twenty pts have been enrolled between November 2018 and July 2019. At the time of data cut off 19 pts were evaluable for response, with one patient too early to assess for response. Patient characteristics are summarized on Table 1; of note 14 (70%) pts had previously been treated with venetoclax in different combinations with HMA's and/or chemotherapy. We observed an overall response rate (ORR) of 42% (n=8), including CR (n=5), CRi (n=1) and PR (n=2). Responses are summarized in Table 2. Among the eight responders there were 4 pts with MRD negative (by flow cytometry) remission. One patient who was considered in CR was taken off study on day 40 because of an underlying invasive fungal sinus infection and concerns of myelosuppression. This patient was transitioned to a lower intensity regimen and remains in remission. Four pts completed 2 inductions, 5 pts received consolidation and 2 pts received GO maintenance before progressing. Unfortunately, none could be transitioned to transplantation due to age or comorbidities. Among responders, median time to ANC &gt;500 was 39 days (30-56) and PLT &gt;50k was 40 days (33-46), median time to ANC &gt;1K was 40 days (31-74) and PLT &gt;100K was 43 days (34-53) after induction (Table 3). With a median follow up of 18.6 months, median OS is 9.1 months (Figure 1) and median duration of response was 10.5 months (figure 2). Adverse events regardless of causality (Table 4) were mainly due to infectious complications. We have not observed treatment related grade 3-4 non-hematological toxicity. Thirty-day mortality was 10% (n=2); both pts died from complications of septicemia. Three additional pts (15%) died within 60 days of treatment, including 2 pts with progressive disease and 1 patient on day 58 after withdrawing care due to infections and 2 aplastic bone marrow examinations on days 14 and 46 of treatment, respectively. CONCLUSION: In this preliminary report, the combination of CPX-351 and GO appears to be active with acceptable toxicities in this high-risk disease population. There are concerns for significant myelosuppression and infectious complications. Disclosures Kadia: Cyclacel: Research Funding; Ascentage: Research Funding; Astellas: Research Funding; Novartis: Honoraria; Genentech: Honoraria, Research Funding; JAZZ: Honoraria, Research Funding; Incyte: Research Funding; Celgene: Research Funding; Pulmotec: Research Funding; Cellenkos: Research Funding; Astra Zeneca: Research Funding; Amgen: Research Funding; Pfizer: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding. Faderl:Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Sasaki:Pfizer Japan: Consultancy; Otsuka: Honoraria; Novartis: Consultancy, Research Funding; Daiichi Sankyo: Consultancy. Daver:Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Servier: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novimmune: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Trovagene: Research Funding; Fate Therapeutics: Research Funding; ImmunoGen: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees. DiNardo:Syros: Honoraria; Agios: Consultancy, Honoraria, Research Funding; MedImmune: Honoraria; Takeda: Honoraria; Notable Labs: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Jazz: Honoraria; Novartis: Consultancy; ImmuneOnc: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Calithera: Research Funding; Celgene: Consultancy, Honoraria, Research Funding. Jabbour:Adaptive Biotechnologies: Other: Advisory role, Research Funding; BMS: Other: Advisory role, Research Funding; Amgen: Other: Advisory role, Research Funding; Takeda: Other: Advisory role, Research Funding; Genentech: Other: Advisory role, Research Funding; Pfizer: Other: Advisory role, Research Funding; AbbVie: Other: Advisory role, Research Funding. Pemmaraju:Stemline Therapeutics: Honoraria, Research Funding; LFB Biotechnologies: Honoraria; Pacylex Pharmaceuticals: Consultancy; Plexxikon: Research Funding; MustangBio: Honoraria; Roche Diagnostics: Honoraria; Samus Therapeutics: Research Funding; DAVA Oncology: Honoraria; Cellectis: Research Funding; Affymetrix: Other: Grant Support, Research Funding; Daiichi Sankyo: Research Funding; AbbVie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Incyte Corporation: Honoraria; SagerStrong Foundation: Other: Grant Support; Celgene: Honoraria; Blueprint Medicines: Honoraria. Konopleva:AbbVie: Consultancy, Research Funding; Kisoji: Consultancy; Calithera: Research Funding; Amgen: Consultancy; Sanofi: Research Funding; Ascentage: Research Funding; Reata Pharmaceutical Inc.;: Patents & Royalties: patents and royalties with patent US 7,795,305 B2 on CDDO-compounds and combination therapies, licensed to Reata Pharmaceutical; Genentech: Consultancy, Research Funding; Rafael Pharmaceutical: Research Funding; Forty-Seven: Consultancy, Research Funding; F. Hoffmann La-Roche: Consultancy, Research Funding; Ablynx: Research Funding; Agios: Research Funding; AstraZeneca: Research Funding; Stemline Therapeutics: Consultancy, Research Funding; Eli Lilly: Research Funding; Cellectis: Research Funding. Garcia-Manero:Acceleron Pharmaceuticals: Consultancy, Honoraria; AbbVie: Honoraria, Research Funding; Novartis: Research Funding; Onconova: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy; H3 Biomedicine: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amphivena Therapeutics: Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding. Andreeff:Daiichi-Sankyo; Jazz Pharmaceuticals; Celgene; Amgen; AstraZeneca; 6 Dimensions Capital: Consultancy; Amgen: Research Funding; Centre for Drug Research & Development; Cancer UK; NCI-CTEP; German Research Council; Leukemia Lymphoma Foundation (LLS); NCI-RDCRN (Rare Disease Clin Network); CLL Founcdation; BioLineRx; SentiBio; Aptose Biosciences, Inc: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo; Breast Cancer Research Foundation; CPRIT; NIH/NCI; Amgen; AstraZeneca: Research Funding. Kantarjian:Jazz Pharma: Research Funding; Novartis: Research Funding; Agios: Honoraria, Research Funding; Ariad: Research Funding; Amgen: Honoraria, Research Funding; Takeda: Honoraria; AbbVie: Honoraria, Research Funding; BMS: Research Funding; Pfizer: Honoraria, Research Funding; Astex: Research Funding; Daiichi-Sankyo: Research Funding; Immunogen: Research Funding; Cyclacel: Research Funding; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ravandi:Amgen: Consultancy, Honoraria, Research Funding; Macrogenics: Research Funding; Orsenix: Consultancy, Honoraria, Research Funding; Xencor: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Astellas: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding. Alvarado:MEI Pharma: Research Funding; Sun Pharma: Research Funding; FibroGen: Research Funding; BerGenBio ASA: Research Funding; Tolero Pharmaceuticals: Research Funding; Daiichi-Sankyo: Research Funding; Jazz Pharmaceuticals: Research Funding; Astex Pharmaceuticals: Research Funding." @default.
• W2983707920 created "2019-11-22" @default.
• W2983707920 creator A5000750846 @default.
• W2983707920 creator A5004888325 @default.
• W2983707920 creator A5010786159 @default.
• W2983707920 creator A5020340537 @default.
• W2983707920 creator A5022647201 @default.
• W2983707920 creator A5025604995 @default.
• W2983707920 creator A5026347795 @default.
• W2983707920 creator A5028081179 @default.
• W2983707920 creator A5028845635 @default.
• W2983707920 creator A5029750735 @default.
• W2983707920 creator A5033646349 @default.
• W2983707920 creator A5035605515 @default.
• W2983707920 creator A5048285635 @default.
• W2983707920 creator A5061026876 @default.
• W2983707920 creator A5070065917 @default.
• W2983707920 creator A5071687115 @default.
• W2983707920 creator A5080350639 @default.
• W2983707920 creator A5088307376 @default.
• W2983707920 creator A5090435894 @default.
• W2983707920 date "2020-11-05" @default.
• W2983707920 modified "2023-10-15" @default.
• W2983707920 title "Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)" @default.
• W2983707920 doi "https://doi.org/10.1182/blood-2020-142570" @default.
• W2983707920 hasPublicationYear "2020" @default.
• W2983707920 type Work @default.
• W2983707920 sameAs 2983707920 @default.
• W2983707920 citedByCount "2" @default.
• W2983707920 countsByYear W29837079202021 @default.
• W2983707920 crossrefType "journal-article" @default.
• W2983707920 hasAuthorship W2983707920A5000750846 @default.
• W2983707920 hasAuthorship W2983707920A5004888325 @default.
• W2983707920 hasAuthorship W2983707920A5010786159 @default.
• W2983707920 hasAuthorship W2983707920A5020340537 @default.
• W2983707920 hasAuthorship W2983707920A5022647201 @default.
• W2983707920 hasAuthorship W2983707920A5025604995 @default.
• W2983707920 hasAuthorship W2983707920A5026347795 @default.
• W2983707920 hasAuthorship W2983707920A5028081179 @default.
• W2983707920 hasAuthorship W2983707920A5028845635 @default.
• W2983707920 hasAuthorship W2983707920A5029750735 @default.
• W2983707920 hasAuthorship W2983707920A5033646349 @default.
• W2983707920 hasAuthorship W2983707920A5035605515 @default.
• W2983707920 hasAuthorship W2983707920A5048285635 @default.
• W2983707920 hasAuthorship W2983707920A5061026876 @default.
• W2983707920 hasAuthorship W2983707920A5070065917 @default.
• W2983707920 hasAuthorship W2983707920A5071687115 @default.
• W2983707920 hasAuthorship W2983707920A5080350639 @default.
• W2983707920 hasAuthorship W2983707920A5088307376 @default.
• W2983707920 hasAuthorship W2983707920A5090435894 @default.
• W2983707920 hasConcept C10205521 @default.
• W2983707920 hasConcept C104317684 @default.
• W2983707920 hasConcept C126322002 @default.
• W2983707920 hasConcept C142424586 @default.
• W2983707920 hasConcept C143998085 @default.
• W2983707920 hasConcept C150194340 @default.
• W2983707920 hasConcept C176290653 @default.
• W2983707920 hasConcept C185592680 @default.
• W2983707920 hasConcept C190727270 @default.
• W2983707920 hasConcept C2776012956 @default.
• W2983707920 hasConcept C2777198975 @default.
• W2983707920 hasConcept C2778041864 @default.
• W2983707920 hasConcept C2778461978 @default.
• W2983707920 hasConcept C2778623314 @default.
• W2983707920 hasConcept C2778729363 @default.
• W2983707920 hasConcept C2781021840 @default.
• W2983707920 hasConcept C28328180 @default.
• W2983707920 hasConcept C54355233 @default.
• W2983707920 hasConcept C55493867 @default.
• W2983707920 hasConcept C71924100 @default.
• W2983707920 hasConcept C86803240 @default.
• W2983707920 hasConcept C87355193 @default.
• W2983707920 hasConcept C90924648 @default.
• W2983707920 hasConceptScore W2983707920C10205521 @default.
• W2983707920 hasConceptScore W2983707920C104317684 @default.
• W2983707920 hasConceptScore W2983707920C126322002 @default.
• W2983707920 hasConceptScore W2983707920C142424586 @default.
• W2983707920 hasConceptScore W2983707920C143998085 @default.
• W2983707920 hasConceptScore W2983707920C150194340 @default.
• W2983707920 hasConceptScore W2983707920C176290653 @default.
• W2983707920 hasConceptScore W2983707920C185592680 @default.
• W2983707920 hasConceptScore W2983707920C190727270 @default.
• W2983707920 hasConceptScore W2983707920C2776012956 @default.
• W2983707920 hasConceptScore W2983707920C2777198975 @default.
• W2983707920 hasConceptScore W2983707920C2778041864 @default.
• W2983707920 hasConceptScore W2983707920C2778461978 @default.
• W2983707920 hasConceptScore W2983707920C2778623314 @default.
• W2983707920 hasConceptScore W2983707920C2778729363 @default.
• W2983707920 hasConceptScore W2983707920C2781021840 @default.
• W2983707920 hasConceptScore W2983707920C28328180 @default.
• W2983707920 hasConceptScore W2983707920C54355233 @default.
• W2983707920 hasConceptScore W2983707920C55493867 @default.
• W2983707920 hasConceptScore W2983707920C71924100 @default.
• W2983707920 hasConceptScore W2983707920C86803240 @default.
• W2983707920 hasConceptScore W2983707920C87355193 @default.
• W2983707920 hasConceptScore W2983707920C90924648 @default.
• W2983707920 hasIssue "Supplement 1" @default.
• W2983707920 hasLocation W29837079201 @default.

• next